[{"id":5545,"regimens":[{"id":10340,"duration":{"id":4319,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11346,"name":"CAP-1002","url":"cure-api2.ncats.io/v1/drugs/11346","rxNorm_id":null,"notes":null},"use_drug":[{"id":6258,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10340}],"created":"2020-05-19T20:30:58.132103Z","updated":"2020-05-20T01:34:48.567872Z","dose":"150 million allogeneic CDCs","frequency":"","route":"IV","severity":null,"severity_detail":null,"comments":null,"report":5545}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7302,"answer":"Clinical assessment","answer_other":"","report":5545},{"id":7303,"answer":"PCR","answer_other":"","report":5545}],"how_diagnosis":[{"id":12120,"answer":"Clinical assessment","answer_other":"","report":5545},{"id":12121,"answer":"Imaging","answer_other":"","report":5545},{"id":12122,"answer":"PCR","answer_other":"","report":5545}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3368,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5545}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-05-19T20:26:09.212933Z","updated":"2020-05-20T01:34:48.558792Z","title":"Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32399655,"doi":"10.1007/s00395-020-0795-1","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32399655","pub_year":2020,"published_authors":"Singh S\r\nChakravarty T\r\nChen P\r\nAkhmerov A\r\nFalk J\r\nFriedman O\r\nZaman T\r\nEbinger JE\r\nGheorghiu M\r\nMarbán L\r\nMarbán E\r\nMakkar RR","article_author_email":"Author email could not be found.","journal":"Basic research in cardiology","abstract":"There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 (COVID-19). Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients (n = 6; age range 19-75 years, 1 female) required ventilatory support (invasive mechanical ventilation, n = 5) with PaO2/FiO2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43-2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89-1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26-0.82 × 103/µl) but had increased in three of these five patients at last follow-up (range 0.23-1.02 × 103/µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"","age":"71-80 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Afib, HTN, HLD, T2DM","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Fever, chills, myalgia, cough, dyspnea, diarrhea","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"12 Days from ICU admission to first infusion of CAP-1002. Cardiosphere-derived cells (CDCs) are stromal/progenitor cells, derived from heart tissue, with a distinctive antigenic profile. Six patients (age range 19–75 years, one woman) underwent IV infusion of CAP-1002 containing 150 million allogeneic CDCs.\r\nThe final ready-to-use cell product in a total volume of 50 ml was infused with a commercially available syringe pump [510(k) cleared for human use] set at an initial rate of 1 ml/min for 10 min (± 30 s). If no signs or symptoms of a potential adverse reaction were observed, the infusion was continued at a rate of 4 ml/min for a total infusion time of 20 min (± 2 min). Upon completion of infusion of the first vial of CAP-1002, and prior to infusion of the second vial, residual material was washed out of the IV tubing with a bolus of 5% HSA (approximately 4 ml over 2 min ± 30 s). The next cell dose of 75 million cells in the second 60-ml syringe was administered to the subject at a rate of 4 ml/min, for a total infusion time of 12.5 (± 1 min). After the second infusion, residual material was washed out of the IV tubing with a bolus of 5% HSA (approximately 4 ml over 2 min ± 30 s).\r\n\r\nPrior treatments\t\r\nLopinavir-ritonavir (× 5 days); Tocilizumab (× 1 dose)","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11346]},{"id":5549,"regimens":[{"id":10351,"duration":{"id":4330,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11346,"name":"CAP-1002","url":"cure-api2.ncats.io/v1/drugs/11346","rxNorm_id":null,"notes":null},"use_drug":[{"id":6269,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10351}],"created":"2020-05-20T01:24:36.043755Z","updated":"2020-05-20T01:33:37.031299Z","dose":"IV infusion of CAP-1002 containing 150 million allogeneic CDCs","frequency":"","route":"IV","severity":null,"severity_detail":null,"comments":null,"report":5549}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7308,"answer":"Clinical assessment","answer_other":"","report":5549},{"id":7309,"answer":"PCR","answer_other":"","report":5549}],"how_diagnosis":[{"id":12127,"answer":"Clinical assessment","answer_other":"","report":5549},{"id":12128,"answer":"Imaging","answer_other":"","report":5549},{"id":12129,"answer":"PCR","answer_other":"","report":5549}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3372,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5549}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-05-20T01:23:52.350932Z","updated":"2020-05-20T01:33:36.997951Z","title":"Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32399655,"doi":"10.1007/s00395-020-0795-1","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32399655","pub_year":2020,"published_authors":"Singh S\r\nChakravarty T\r\nChen P\r\nAkhmerov A\r\nFalk J\r\nFriedman O\r\nZaman T\r\nEbinger JE\r\nGheorghiu M\r\nMarbán L\r\nMarbán E\r\nMakkar RR","article_author_email":"Author email could not be found.","journal":"Basic research in cardiology","abstract":"There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 (COVID-19). Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients (n = 6; age range 19-75 years, 1 female) required ventilatory support (invasive mechanical ventilation, n = 5) with PaO2/FiO2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43-2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89-1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26-0.82 × 103/µl) but had increased in three of these five patients at last follow-up (range 0.23-1.02 × 103/µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"","age":"16-20 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Obesity","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Fevers, chills, diarrhea, cough","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"5 Days from ICU admission to first infusion.\r\nPrevious treatment: HCQ (× 5 days); Tocilizumab (× 1 dose)\r\nCardiosphere-derived cells (CDCs) are stromal/progenitor cells, derived from heart tissue, with a distinctive antigenic profile. IV infusion of CAP-1002 containing 150 million allogeneic CDCs.\r\nThe final ready-to-use cell product in a total volume of 50 ml was infused with a commercially available syringe pump [510(k) cleared for human use] set at an initial rate of 1 ml/min for 10 min (± 30 s). If no signs or symptoms of a potential adverse reaction were observed, the infusion was continued at a rate of 4 ml/min for a total infusion time of 20 min (± 2 min). Upon completion of infusion of the first vial of CAP-1002, and prior to infusion of the second vial, residual material was washed out of the IV tubing with a bolus of 5% HSA (approximately 4 ml over 2 min ± 30 s). The next cell dose of 75 million cells in the second 60-ml syringe was administered to the subject at a rate of 4 ml/min, for a total infusion time of 12.5 (± 1 min). After the second infusion, residual material was washed out of the IV tubing with a bolus of 5% HSA (approximately 4 ml over 2 min ± 30 s).","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11346]},{"id":5550,"regimens":[{"id":10352,"duration":{"id":4331,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11346,"name":"CAP-1002","url":"cure-api2.ncats.io/v1/drugs/11346","rxNorm_id":null,"notes":null},"use_drug":[{"id":6270,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10352}],"created":"2020-05-20T01:36:58.651448Z","updated":"2020-05-20T01:45:25.105335Z","dose":"IV infusion of CAP-1002 containing 150 million allogeneic CDCs","frequency":"","route":"IV","severity":"Inpatient","severity_detail":null,"comments":null,"report":5550}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7310,"answer":"Clinical assessment","answer_other":"","report":5550},{"id":7311,"answer":"PCR","answer_other":"","report":5550}],"how_diagnosis":[{"id":12130,"answer":"Clinical assessment","answer_other":"","report":5550},{"id":12131,"answer":"Imaging","answer_other":"","report":5550},{"id":12132,"answer":"PCR","answer_other":"","report":5550}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3373,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5550}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-05-20T01:36:37.280165Z","updated":"2020-05-20T01:45:25.071992Z","title":"Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Case 3","status":"Approved","anonymous":false,"published":true,"pubmed_id":32399655,"doi":"10.1007/s00395-020-0795-1","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32399655","pub_year":2020,"published_authors":"Singh S\r\nChakravarty T\r\nChen P\r\nAkhmerov A\r\nFalk J\r\nFriedman O\r\nZaman T\r\nEbinger JE\r\nGheorghiu M\r\nMarbán L\r\nMarbán E\r\nMakkar RR","article_author_email":"Author email could not be found.","journal":"Basic research in cardiology","abstract":"There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 (COVID-19). Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients (n = 6; age range 19-75 years, 1 female) required ventilatory support (invasive mechanical ventilation, n = 5) with PaO2/FiO2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43-2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89-1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26-0.82 × 103/µl) but had increased in three of these five patients at last follow-up (range 0.23-1.02 × 103/µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"HTN, HLD, HFpEF, T2DM, Obesity","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Malaise, ADHF (edema, weight gain)","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"7 Days from ICU admission to first infusion.\r\nCardiosphere-derived cells (CDCs) are stromal/progenitor cells, derived from heart tissue, with a distinctive antigenic profile. \r\nIV infusion of CAP-1002 containing 150 million allogeneic CDCs\r\nThe final ready-to-use cell product in a total volume of 50 ml was infused with a commercially available syringe pump [510(k) cleared for human use] set at an initial rate of 1 ml/min for 10 min (± 30 s). If no signs or symptoms of a potential adverse reaction were observed, the infusion was continued at a rate of 4 ml/min for a total infusion time of 20 min (± 2 min). Upon completion of infusion of the first vial of CAP-1002, and prior to infusion of the second vial, residual material was washed out of the IV tubing with a bolus of 5% HSA (approximately 4 ml over 2 min ± 30 s). The next cell dose of 75 million cells in the second 60-ml syringe was administered to the subject at a rate of 4 ml/min, for a total infusion time of 12.5 (± 1 min). After the second infusion, residual material was washed out of the IV tubing with a bolus of 5% HSA (approximately 4 ml over 2 min ± 30 s).\r\n\r\nPrior treatments: HCQ (× 5 days); Tocilizumab (× 1 dose)","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11346]},{"id":5551,"regimens":[{"id":10353,"duration":{"id":4332,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11346,"name":"CAP-1002","url":"cure-api2.ncats.io/v1/drugs/11346","rxNorm_id":null,"notes":null},"use_drug":[{"id":6271,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10353}],"created":"2020-05-20T01:46:52.085819Z","updated":"2020-05-20T01:54:57.746434Z","dose":"IV infusion of CAP-1002 containing 150 million allogeneic CDCs.","frequency":"","route":"IV","severity":null,"severity_detail":null,"comments":null,"report":5551}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7312,"answer":"Clinical assessment","answer_other":"","report":5551},{"id":7313,"answer":"PCR","answer_other":"","report":5551}],"how_diagnosis":[{"id":12133,"answer":"Clinical assessment","answer_other":"","report":5551},{"id":12134,"answer":"Imaging","answer_other":"","report":5551},{"id":12135,"answer":"PCR","answer_other":"","report":5551}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3374,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5551}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-05-20T01:46:01.401949Z","updated":"2020-05-20T01:54:57.713366Z","title":"Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Case 5","status":"Approved","anonymous":false,"published":true,"pubmed_id":32399655,"doi":"10.1007/s00395-020-0795-1","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32399655","pub_year":2020,"published_authors":"Singh S\r\nChakravarty T\r\nChen P\r\nAkhmerov A\r\nFalk J\r\nFriedman O\r\nZaman T\r\nEbinger JE\r\nGheorghiu M\r\nMarbán L\r\nMarbán E\r\nMakkar RR","article_author_email":"Author email could not be found.","journal":"Basic research in cardiology","abstract":"There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 (COVID-19). Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients (n = 6; age range 19-75 years, 1 female) required ventilatory support (invasive mechanical ventilation, n = 5) with PaO2/FiO2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43-2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89-1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26-0.82 × 103/µl) but had increased in three of these five patients at last follow-up (range 0.23-1.02 × 103/µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"CKD, HTN, obesity","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Fever, cough, dyspnea, diarrhea, emesis","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"1 week","additional_info":"3 Days from ICU admission to first infusion\r\n\r\nIV infusion of CAP-1002 containing 150 million allogeneic CDCs. \r\nCardiosphere-derived cells (CDCs) are stromal/progenitor cells, derived from heart tissue, with a distinctive antigenic profile.\r\nThe final ready-to-use cell product in a total volume of 50 ml was infused with a commercially available syringe pump [510(k) cleared for human use] set at an initial rate of 1 ml/min for 10 min (± 30 s). If no signs or symptoms of a potential adverse reaction were observed, the infusion was continued at a rate of 4 ml/min for a total infusion time of 20 min (± 2 min). Upon completion of infusion of the first vial of CAP-1002, and prior to infusion of the second vial, residual material was washed out of the IV tubing with a bolus of 5% HSA (approximately 4 ml over 2 min ± 30 s). The next cell dose of 75 million cells in the second 60-ml syringe was administered to the subject at a rate of 4 ml/min, for a total infusion time of 12.5 (± 1 min). After the second infusion, residual material was washed out of the IV tubing with a bolus of 5% HSA (approximately 4 ml over 2 min ± 30 s).\r\n\r\nPrior treatment: HCQ (× 5 days); Tocilizumab (× 1 dose)","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11346]}]